Tools




news

RSS

19/6/2012

Thesis of Ignasi Buch: "Investigation of protein-ligand interactions using high-throughput all-atom molecular dynamics simulations"

On Friday, 29th of June, Ignasi Buch, member of the Computational Biophysics Group of GRIB (IMIM-UPF) will defend his thesis at 15:00 in the Auditorium of PRBB.

More information

19/6/2012

GRIB participates at BIO Boston 2012, the top biotechnology convention in the world

Connect, partner and innovate. This is the slogan for the twentieth edition of the BIO International Convention, held 18 to 21 June 2012 in the city of Boston (Massachusetts, United States). BIO is the most important international business meeting in the biotechnology arena. This year, it will bring together more than 15,000 delegates from 65 countries, more than 900 exhibitors and 1,800 companies. In addition to the exhibition area, it also features a Business Forum for partnering meetings, which in 2011 generated more than 21,000 one-to-one meetings.

The GRIB (IMIM-UPF) takes part of the Catalan delegation made up of 50 companies and 22 organizations from the biotechnology and biomedicine sector. At the 2012 edition, Spain will have the most important international pavilion, with Catalonia making up more than 60%, ahead of countries like Brazil, China, India and Russia. The Spanish pavilion will be located at a strategic point, just in front of the host State of Massachusetts.

More information

20/6/2012

Thesis of Khademul Islam: Delineating epigenetic regulatory mechanisms of cell proliferation and differentiation"

On Monday, 25th of June, Khademul Islam, member of the Biomedical Genomics Group of GRIB (IMIM-UPF) will defend his thesis at 14:00 in the Auditorium of PRBB.

More information

En la complexitat dels éssers vius intervenen propietats físico-químiques del medi cel·lular

Un treball dirigit per Eduardo Eyras, investigador ICREA i responsable del Grup de Regulació Genòmica del GRIB (IMIM-UPF) mostra com les formes o estructures secundàries d'ARN regulen l'splicing o empalmament alternatiu en cèl·lules de llevat (Saccharomyces cerevisiae) emprades com a model experimental.

S'ha comprovat que aquestes conformacions secundàries de l'ARN estan modificades per propietats físiques i químiques intrínseques de la cèl·lula, com ara la temperatura i el pH.

Treball de referència:  Plass M, Codony-Servat C, Ferreira PG, Vilardell J, Eyras E. RNA secondary structure mediates alternative 3'ss selection in Saccharomyces cerevisiae. RNA, 2012.

More information

4/5/2012

eTOX makes progress on predictive toxicology

IMI project eTOX, coordinated by GRIB (IMIM-UPF) is making progress towards its goal of developing a predictive toxicology system called eTOXsys, which is now at the prototype stage. In a recent article in the International Journal of Molecular Sciences, the eTOX partners describe eTOXsys as 'a software tool able to provide useful toxicological risk and hazard assessment.' Users will simply need to enter a small amount of information, such as the structure of the compound they are interested in, and the system will use a series of advanced models to deliver information on the likelihood of potential toxicity of the compound.

Article reference: Briggs K, Cases M, Heard DJ, Pastor M, Pognan F, Sanz F, Schwab CH, Steger-Hartmann T, Sutter A, Watson DK, Wichard JD. Inroads to Predict in Vivo Toxicology -An Introduction to the eTOX Project. Int J Mol Sci, 2012; 13(3), 3820-3846. PMID 22489185. DOI 10.3390/ijms13033820.

More information

2/5/2012

Identified 115 proteins that would allow designing new generation anti-cancer drugs; The new drugs would be more effective and with fewer side effects.

Researchers from the Chemogenomics Group of GRIB (IMIM/ UPF) have identified 115 proteins in silico (via computer simulation) that could be highly relevant to treat colon-rectal cancer, since they would make it possible to define the strategy to design new generation anti-cancer drugs.

According to Jordi Mestres, the coordinator of the Chemogenomics Laboratory of the GRIB “The basis of this strategy is a list of molecules that, experimentally, have been proven to be significantly more toxic for tumour cells than for healthy ones and another list of molecules that are more toxic for healthy cells than for tumour ones. These two lists of molecules are computationally processed with a methodology that allows predicting those proteins for which each molecule will have an affinity, identifying potential biological targets to develop new anti-cancer drugs”.

Reference Article: A Chemocentric Approach to the Identification of Cancer Targets”. Beáta Flachner, Zsolt Lörincz, Angelo Carotti, Orazio Nicolotti, Praveena Kuchipudi, Nikita Remez, Ferran Sanz, József Tóvári, Miklós J. Szabó, Béla Bertók, Sándor Cseh, Jordi Mestres, and György Dormán. PLoS ONE 2012, 7: e0035582. http://dx.plos.org/10.1371/journal.pone.0035582

More information

27/4/2012

GRIB EXPO, a unique opportunity to bring Biomedical Informatics closer to the clinical sector and to industrial innovation

Last thursday 26 April, saw the conclusion in Barcelona of the first edition of GRIB EXPO, a symposium organised by the Research Programme on Biomedical Informatics (GRIB - IMIM/ UPF). The aim of the EXPO was to bring Biomedical Informatics closer to the clinical sector and to industrial innovation, with a view to promoting the open exchange of ideas and cooperation.

With around a hundred attendees from both the industrial and the clinical sectors and the participation of more than 80 high-level scientific researchers focused on Biomedical Informatics, GRIB EXPO was a unique opportunity to explore how this discipline can offer innovative strategies in both basic and clinical research as well as in industrial innovation, especially as regards the pharmaceutical and biotech sectors. 

Ferran Sanz, Director of GRIB, explained that “the symposium responds to one of the GRIB’s strategic objectives, which is to increase cooperation with the business fabric while initiating an approach to the clinical sector where Biomedical Informatics can offer numerous innovative solutions of huge practical value”. These would include predicting the toxicity of potential new medicines or analysing the huge amount of genetic information produced by advanced sequencing techniques.

Dr Andrés Fernández, Director of the Area of Innovation in Biotechnology at Laboratorios Ferrer qualified the event as “an excellent forum to identify new technological approaches that increase the effectiveness of Drug Discovery and that allows making straightforward progress in simulation and virtualization processes. A unique opportunity to explore collaborations between the academic and industrial sectors”.

More information

Come to the GRIB EXPO the 26th of April, 2012

Come to the GRIB EXPO the 26th of April, 2012, a new scientific exhibition on biomedical informatics. You will have the chance to interact with scientist working on computational tools to shape the future of healthcare and drug discovery.

The GRIB EXPO is opened to academic and industrial organisations within the PRBB and beyond. It will give you the opportunity to present your know-how to a wide scientific community within and outside PRBB.

The GRIB EXPO will take place at the Universitat Pompeu Fabra, Sala d’exposicions, Ramón Trias Fargas, 25-27.

Please confirm your attendance by email to Carina Oliver, coliver@imim.es

More information

Celebrada la V Conferencia Anual de las Plataformas de Investigación Biomédica

Bajo el lema Fomentando la Open Innovation, los más de 230 asistentes que asistieron en Barcelona a la V Conferencia Anual de investigación biomédica, abordaron la necesidad de seguir promoviendo los modelos de cooperación publico-privada basados en el concepto de open innovation en el ámbito de la I+D+i biomédica. Todas las presentaciones y vídeos están disponibles en www.medicamentos-innovadores.org. El GRIB coordina junto con Farmaindustria la Plataforma Española de Medicamentos Innovadores, coorganizadores del evento.

More information



Site Information